| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702750 | Urologic Oncology: Seminars and Original Investigations | 2017 | 8 Pages |
Abstract
These results suggest at least partially nonoverlapping effects of docetaxel and androgen deprivation therapy and hence help to understand recent clinical findings. A further elucidation of the mode of action of docetaxel would have important implications to optimize current treatment strategies and biomarker development for men with metastatic prostate cancer.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Josef M.D., Konstanze M.D., Martina Heller, Julia D.V.M., Ph.D., Yanis Ph.D., Jielin M.D., Markus M.D., Stefan M.D.,